EyePoint Pharmaceuticals, Inc. (EYPT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EYPT Revenue Growth
Revenue Breakdown (FY 2024)
EYPT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
EYPT Revenue Analysis (2014–2025)
As of May 8, 2026, EyePoint Pharmaceuticals, Inc. (EYPT) generated trailing twelve-month (TTM) revenue of $31.4 million, reflecting significant decline in growth of -94.6% year-over-year. The most recent quarter (Q4 2025) recorded $620,000 in revenue, down 35.8% sequentially.
Looking at the longer-term picture, EYPT's 5-year compound annual growth rate (CAGR) stands at -1.8%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $46.0 million in 2023.
Revenue diversification analysis shows EYPT's business is primarily driven by License And Collaboration Agreement (83%), Product (7%), and Y U T I Q Product (7%). With over half of revenue concentrated in License And Collaboration Agreement, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including OCUL (-12.8% YoY), and NVCR (+8.5% YoY), EYPT has underperformed the peer group in terms of revenue growth. Compare EYPT vs OCUL →
EYPT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EYPTCurrent | $31M | -94.6% | -1.8% | -776.0% | |
 OCUL | $52M | -12.8% | +24.4% | -521.0% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% |
EYPT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $31.4M | -27.5% | $29.3M | 93.4% | $-243,434,000 | -776.0% |
| 2024 | $43.3M | -6.0% | $39.6M | 91.4% | $-145,854,000 | -337.1% |
| 2023 | $46.0M | +11.1% | $41.4M | 89.9% | $-75,067,000 | -163.1% |
| 2022 | $41.4M | +12.1% | $33.1M | 79.9% | $-99,637,000 | -240.6% |
| 2021 | $36.9M | +7.3% | $28.8M | 77.9% | $-55,276,000 | -149.6% |
| 2020 | $34.4M | +69.1% | $28.6M | 83.1% | $-37,290,000 | -108.3% |
| 2019 | $20.4M | +587.8% | $17.7M | 86.8% | $-47,861,000 | -235.0% |
| 2018 | $3.0M | -60.7% | $-15,541,000 | -524.9% | $-26,274,000 | -887.3% |
| 2017 | $7.5M | +365.4% | $7.5M | 100.0% | $-18,576,000 | -246.4% |
| 2016 | $1.6M | -93.9% | $805K | 49.7% | $-21,774,000 | -1344.1% |
See EYPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EYPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EYPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEYPT — Frequently Asked Questions
Quick answers to the most common questions about buying EYPT stock.
Is EYPT's revenue growth accelerating or slowing?
EYPT revenue declined -94.6% year-over-year, contrasting with the 5-year CAGR of -1.8%. TTM revenue fell to $31M. This reverses the prior growth trend.
What is EYPT's long-term revenue growth rate?
EyePoint Pharmaceuticals, Inc.'s 5-year revenue CAGR of -1.8% reflects the variable expansion pattern. Current YoY growth of -94.6% is below this long-term average.
How is EYPT's revenue distributed by segment?
EYPT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.